FrancophonIA/ELRC3.0 huggingface dataset:
English: The recommended dose is 80 mg osimertinib once a day until disease progression or unacceptable toxicity.
Croatian: Preporučena doza je 80 mg osimertiniba jedanput dnevno do progresije bolesti ili razvoja neprihvatljive toksičnosti.
English: The tablet should be swallowed whole with water and it should not be crushed, split or chewed.
Croatian: Tabletu treba progutati cijelu s vodom, te se ne smije drobiti, lomiti ili žvakati.
English: The C30 was assessed every 6 weeks before and after progression.
Croatian: Upitnik C30 ispunjavao se svakih 6 tjedana prije i nakon progresije.
English: Changes in cardiac contractility
Croatian: Promjene srčane kontraktilnosti
English: In vitro plasma protein binding of osimertinib is 94.7% (5.3% free).
Croatian: In vitro, vezanje osimertiniba na proteine u plazmi je 94,7% (5,3% nevezanog).
English: • TAGRISSO may interfere with how well oral hormonal contraceptives work.
Croatian: • TAGRISSO može utjecati na djelovanje oralnih hormonskih kontraceptiva.
English: You must also do this after completing treatment with TAGRISSO:
Croatian: Toga se također morate pridržavati i nakon završetka liječenja lijekom TAGRISSO:
English: TAGRISSO as monotherapy is indicated for:
Croatian: TAGRISSO je u monoterapiji indiciran za:
English: Seventy-two percent (72%) of patients were never smokers, 100% of patients had a World Health Organization (WHO) performance status of 0 or 1.
Croatian: Sedamdeset i dva posto (72%) bolesnika nije nikada pušilo, a 100% njih imalo je WHO (World Health Organization) funkcionalni status od 0 ili 1.
English: In addition, the corresponding frequency category for each adverse reaction is based on the CIOMS III convention and is defined as: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from available data).
Croatian: Nadalje, odgovarajuće kategorije učestalosti svih nuspojava definirane su na temelju CIOMS III konvencije: vrlo često (≥1/10); često (≥1/100 i <1/10); manje često (≥1/1000 i <1/100); rijetko (≥1/10 000 i <1/1000); vrlo rijetko (<1/10 000); nepoznato (ne može se procijeniti iz dostupnih podataka).
English: The findings present following 1 month of dosing were largely reversible within 1 month of cessation of dosing with the exception of partial recovery for some of the corneal changes.
Croatian: Promjene koje su nastale nakon mjesec dana doziranja većinom su bile reverzibilne u roku od 1 mjeseca od prekida doziranja, uz iznimku djelomičnog oporavka nekih promjena na rožnici.
English: Treatment with this medicinal product should be interrupted pending investigation of these symptoms.
Croatian: Liječenje ovim lijekom treba se prekinuti dok se navedeni simptomi ne istraže.
English: If dose reduction is necessary, then the dose should be reduced to 40 mg taken once daily.
Croatian: Ako je potrebno smanjenje doze, ona se treba smanjiti na 40 mg jedanput dnevno.
English: • The recommended dose is one 80 mg tablet each day.
Croatian: • Preporučena doza je jedna tableta od 80 mg svaki dan.
English: Older patients reported more Grade 3 or higher adverse reactions compared to younger patients (13.4% versus 9.3%).
Croatian: Stariji bolesnici prijavili su više nuspojava stupnja 3 ili višeg, u usporedbi s mlađim bolesnicima (13,4% naspram 9,3%).
English: TAGRISSO may affect how well the following medicines work and/or increase side effects of these medicines:
Croatian: TAGRISSO može utjecati na djelovanje sljedećih lijekova i/ili povećati njihove nuspojave:
English: • This medicine does not require any special storage conditions.
Croatian: • Ovaj lijek ne zahtjeva posebne uvjete čuvanja.
English: QTc interval prolongation with signs/symptoms of serious arrhythmia
Croatian: Produljenje QTc intervala uz znakove/simptome ozbiljne aritmije
English: If the patient is unable to swallow the tablet, the tablet may first be dispersed in 50 mL of non-carbonated water.
Croatian: Ako bolesnik ne može progutati tabletu, tableta se može prije primjene dispergirati (raspršiti) u 50 ml negazirane vode.
English: Do not breast-feed while taking this medicine.
Croatian: Dojenje Nemojte dojiti tijekom uzimanja ovog lijeka.
English: TAGRISSO may be restarted at the same dose (80 mg) or a lower dose (40 mg)
Croatian: Primjena lijeka TAGRISSO može se ponovno započeti pri istoj dozi (80 mg) ili pri smanjenjoj dozi (40 mg)
English: Similarly, the exposure to metabolite AZ5104 decreased by 82% for the AUC and 78% for Cmax.
Croatian: Slično, izloženost metabolitu AZ5104 smanjila se za 82% za vrijednost AUC i 78% za vrijednost Cmax.
English: • Men - keep using contraception for 4 months after.
Croatian: • Muškarci - nastavite koristiti kontracepciju tijekom 4 mjeseca nakon liječenja.
English: No dosage adjustment is required due to patient age, body weight, gender, ethnicity and smoking status (see section 5.2).
Croatian: Nije potrebna prilagodba doze s obzirom na dob, tjelesnu težinu, spol, etničku pripadnost ili pušački status bolesnika (vidjeti dio 5.2).
English: • If you plan to become pregnant after taking the last dose of this medicine, ask your doctor for advice.
Croatian: • Ako planirate zatrudnjeti nakon uzimanja posljednje doze ovog lijeka, upitajte svog liječnika za savjet.
English: Cardiac QTc interval greater than 500 msec on at least 2 separate ECGs
Croatian: Srčani QTc interval veći od 500 msek na najmanje 2 različita EKG-a
English: Assessment of EGFR mutation status
Croatian: Procjena statusa mutacija EGFR-a
English: Carcinogenicity studies have not been performed with osimertinib.
Croatian: Ispitivanja kancerogenosti nisu provedena s osimertinibom.
English: Non-clinical data indicate that osimertinib and its metabolite (AZ5104) inhibit the h-ERG channel, and QTc prolonging effect cannot be excluded.
Croatian: Neklinički podaci ukazuju da osimertinib i njegov metabolit (AZ5104) inhibiraju h-ERG kanal te se ne može isključiti učinak na produljenje QTc intervala.
English: Pharmacotherapeutic group: antineoplastic agents, protein kinase inhibitors; ATC code: L01XE35.
Croatian: Farmakoterapijska skupina: antineoplastični lijekovi, inhibitori protein kinaze ATK oznaka: L01XE35.
English: There are no data on the effect of TAGRISSO on human fertility.
Croatian: Nema podataka o učinku lijeka TAGRISSO na plodnost u ljudi.
English: These findings were seen at clinically relevant plasma concentrations.
Croatian: Ovi nalazi zamijećeni su pri klinički relevantnim koncentracijama u plazmi.
English: If you take more TAGRISSO than you should If you take more than your normal dose, contact your doctor or nearest hospital straight away.
Croatian: Ako uzmete više lijeka od Vaše uobičajene doze, odmah kontaktirajte svog liječnika ili se javite u najbližu bolnicu.
English: • Rifabutin or rifampicin - used for tuberculosis (TB).
Croatian: • Rifabutin ili rifampicin - koriste se za liječenje tuberkuloze (TB).
English: Represents the incidence of patients who had a QTcF prolongation >500msec.
Croatian: Predstavlja incidenciju bolesnika koji su imali produljenje QTcF intervala na > 500 msek.
English: Haematological events
Croatian: Hematološki događaji
English: The safety and efficacy of this medicinal product has not been established in patients with severe hepatic impairment.
Croatian: Sigurnost i djelotvornost ovog lijeka nisu ustanovljene u bolesnika s teškim oštećenjem funkcije jetre.
English: Exposure at doses of 20 mg/kg and above during organogenesis caused reduced foetal weights but no adverse effects on external or visceral foetal morphology.
Croatian: Izloženost pri dozama od 20 mg/kg i višima tijekom organogeneze uzrokovala je smanjenu tjelesnu težinu fetusa, ali ne i štetne učinke na vanjsku i visceralnu morfologiju fetusa.
English: QTc interval prolongation may lead to an increased risk for ventricular tachyarrhythmias (e.g. torsade de pointes) or sudden death.
Croatian: Produljenje QTc intervala može dovesti do povećanog rizika od ventrikularnih tahiaritmija (npr. torsade de pointes) ili iznenadne smrti.
English: The European Medicines Agency has waived the obligation to submit the results of studies with TAGRISSO in all subsets of the paediatric population in NSCLC (see section 4.2 for information on paediatric use).
Croatian: Europska agencija za lijekove izuzela je obvezu podnošenja rezultata ispitivanja lijeka TAGRISSO u svim podskupinama pedijatrijske populacije za NSCLC (vidjeti dio 4.2 za informacije o pedijatrijskoj primjeni).
English: Osimertinib may increase the exposure of breast cancer resistant protein (BCRP) and P-glycoprotein (P-gp) substrates.
Croatian: Osimertinib može povećati izloženost supstratima proteina rezistencije raka dojke (engl. breast cancer resistant protein, BCRP) i P-glikoproteina (P-gp).
English: • The other ingredients are mannitol, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, sodium stearyl fumarate, polyvinyl alcohol, titanium dioxide, macrogol 3350, talc, yellow iron oxide, red iron oxide, black iron oxide (see section 2 “Information on other ingredients in this medicine”).
Croatian: • Ostali sastojci su manitol, mikrokristalična celuloza, nisko supstituirana hidroksipropilceluloza, natrijev stearilfumarat, poli(vinilni alkohol), titanijev dioksid, makrogol 3350, talk, žuti željezov oksid, crveni željezov oksid, crni željezov oksid (pogledajte dio 2. „Informacije o drugim sastojcima lijeka“).
English: • If you develop watery eyes, sensitivity to light, eye pain, eye redness, or vision changes.
Croatian: • Suzenje očiju, osjetljivost na svjetlost, bol u oku, crvenilo oka ili promjene vida.
English: Name and address of the manufacturer responsible for batch release AstraZeneca AB
Croatian: Naziv i adresa proizvođača odgovornog za puštanje serije lijeka u promet AstraZeneca AB
English: • Sudden difficulty in breathing together with a cough or fever - this may be a sign of inflamed lungs (a condition called ‘interstitial lung disease').
Croatian: • Iznenadne poteškoće u disanju, zajedno s kašljem ili vrućicom - to mogu biti znakovi upale pluća (stanja nazvanog „intersticijska bolest pluća“).
English: Reintroduction of TAGRISSO should be considered only after careful consideration of the individual patient's benefits and risk.
Croatian: Ponovna primjena lijeka TAGRISSO može biti razmotrena samo nakon pažljive procjene odnosa rizika i koristi za pojedinog bolesnika.
English: • Efavirenz and etravirine - used to treat HIV infections/AIDS.
Croatian: • Efavirenz i etravirin - koriste se za liječenje infekcije HIV-om/AIDS-a.
English: All cases were isolated incidents of patients taking an additional daily dose of TAGRISSO in error, without any resulting clinical consequences.
Croatian: Svi slučajevi su bili izolirani slučajevi bolesnika koji su greškom uzeli dodatnu dozu lijeka TAGRISSO, bez ikakvih kliničkih posljedica.
English: Studies in animals have shown reproductive toxicity (embryolethality, reduced foetal growth, and neonatal death, see section 5.3).
Croatian: Ispitivanja na životinjama pokazala su reproduktivnu toksičnost (embrioletalnost, smanjen rast fetusa i smrt novorođenčeta, vidjeti dio 5.3).
English: TAGRISSO contains the active substance osimertinib, which belongs to a group of medicines called protein kinase inhibitors which are used to treat cancer.
Croatian: TAGRISSO sadrži djelatnu tvar osimertinib, koja pripada skupini lijekova pod nazivom inhibitori protein kinaze, koji se koriste za liječenje raka.
English: However, if a plasma-based ctDNA test is used and the result is negative, it is advisable to follow-up with a tissue test wherever possible due to the potential for false negative results using a plasma-based test.
Croatian: Međutim, ako se pri korištenju testa temeljenog na ctDNK dobivenoj iz uzorka plazme dobije negativan rezultat, preporučuje se provesti nastavno testiranje s uzorkom tkiva kada god je to moguće, zbog mogućih lažno negativnih rezultata pri korištenju testa koji se temelji na uzorku plazme.
English: This is because TAGRISSO can affect the way some other medicines work.
Croatian: Razlog tome je što TAGRISSO može utjecati na način djelovanja nekih lijekova.
English: In FLAURA and AURA3 (N=1142), 43% of patients were 65 years of age and older, and 13% were 75 years of age and older.
Croatian: U ispitivanjima FLAURA i AURA3 (N=1142), 43% bolesnika bilo je u dobi od 65 i više godina, dok je njih 13% bilo u dobi od 75 i više godina.
English: See also Section 2.
Croatian: Pogledajte također dio 2.
English: If any of the above apply to you (or you are not sure), talk to your doctor, pharmacist or nurse before taking this medicine.
Croatian: Ako se bilo što od gore navedenog odnosi na Vas (ili ako niste sigurni), obratite se svom liječniku, ljekarniku ili medicinskoj sestri prije nego uzmete ovaj lijek.
English: • If your cancer has progressed while you were being treated with other protein kinase inhibitor medicines, it means that your cancer contains a gene defect called ‘T790M'.
Croatian: • Ako je Vaš rak uznapredovao dok ste se liječili drugim inhibitorom protein kinaze, to znači da on sadrži oštećenje gena koje se zove „T790M“.
English: • Diarrhoea - this may come and go during treatment.
Croatian: • Proljev - može se javljati i nestajati tijekom liječenja.
English: Moderate CYP3A4 inducers (e.g. bosentan, efavirenz, etravirine, modafinil) may also decrease osimertinib exposure and should be used with caution, or avoided when possible.
Croatian: Umjereni induktori CYP3A4 (npr. bosentan, efavirenz, etravirin, modafinil) također mogu smanjiti izloženost osimertinibu te ih je potrebno primjenjivati s oprezom ili izbjegavati, kada je to moguće.
English: In human plasma, parent osimertinib accounted for 0.8%, with the 2 metabolites contributing 0.08% and 0.07% of the total radioactivity with the majority of the radioactivity being covalently bound to plasma proteins.
Croatian: U ljudskoj plazmi, ishodišni spoj osimertinib doprinio je 0,8%, dok su 2 metabolita doprinijela 0,08% odnosno 0,07% ukupnoj radioaktivnosti uz većinu radioaktivnosti kovalentno vezane na proteine u plazmi.
English: Unchanged osimertinib accounted for approximately 2% of the elimination with 0.8% in urine and 1.2% in faeces.
Croatian: Nepromijenjeni osimertinib čini približno 2% eliminacije, od čega je 0,8% u urinu i 1,2% u fecesu.
English: Objective response rates by BICR above 50% were observed in all predefined subgroups analysed, including line of therapy, ethnicity, age and region.
Croatian: Stopa objektivnog odgovora iznad 50% prema BICR-u zamijećena je za sve analizirane prethodno definirane podskupine, uključujući liniju liječenja, etničku pripadnost, dob i regiju.
English: • Add 50 mL (about two-thirds of a tumblerful) of still (non-fizzy) water - do not use any other liquids.
Croatian: • Dodajte 50 ml negazirane vode - nemojte koristiti nikakvu drugu tekućinu.
English: These findings occurred at plasma concentrations that were below those seen in patients at the 80 mg therapeutic dose.
Croatian: Ove su promjene nastale pri koncentracijama u plazmi nižima od onih nađenih u bolesnika pri primjeni terapijske doze od 80 mg.
English: Osimertinib pharmacokinetic parameters have been characterised in healthy subjects and NSCLC patients.
Croatian: Farmakokinetički parametri osimertiniba utvrđeni su u zdravih ispitanika i bolesnika s NSCLC-om.
English: • If TAGRISSO is the first protein kinase inhibitor medicine you are receiving, it means that your cancer contains defects in the EGFR gene, for example ‘exon 19 deletions' or ‘exon 21 substitution mutations'.
Croatian: • Ako je TAGRISSO prvi inhibitor protein kinaze koji primate, to znači da Vaš rak sadrži oštećenje EGFR gena koje se, na primjer, zove „delecija eksona 19“ ili „supstitucija eksona 21“
English: Adjusted mean and estimated differences obtained from a Mixed Model Repeated Measures (MMRM) analysis.
Croatian: Prilagođena srednja vrijednost i procijenjene razlike dobivene analizom na temelju miješanog modela ponovljenih mjerenja (MMRM).
English: There is no specific treatment in the event of TAGRISSO overdose.
Croatian: Ne postoji specifično liječenje u slučaju predoziranja lijekom TAGRISSO.
English: The safety and efficacy of this medicinal product has not been established in patients with end-stage renal disease [creatinine clearance (CLcr) <15 mL/min, calculated by the Cockcroft and Gault equation], or on dialysis.
Croatian: Sigurnost i djelotvornost ovog lijeka nisu ustanovljene u bolesnika sa završnim stadijem bolesti bubrega [klirens kreatinina (CLcr) <15 ml/min, izračunato pomoću CockcroftGaultove jednadžbe], ili koji su na dijalizi.
English: 4.4 Special warnings and precautionsfor use
Croatian: 4.4 Posebna upozorenja i mjere opreza pri uporabi
English: • Stevens-Johnson syndrome, which can appear as reddish target-like macules or circular patches often with central blisters on the trunk, skin peeling, ulcers of mouth, throat, nose, genitals and eyes and be preceded by fever and flu-like symptoms.
Croatian: • Stevens-Johnsonov sindrom, koji se može pojaviti kao crvenkaste mrlje nalik na metu ili u obliku okruglih područja često sa središnjim mjehurićima na trupu, ljuštenjem kože, ranicama u ustima, grlu, nosu, na genitalijama i očima, a mogu mu prethoditi vrućica i simptomi nalik gripi.
English: What TAGRISSO contains
Croatian: Što TAGRISSO sadrži
English: Osimertinib did not cause genetic damage in in vitro and in vivo assays.
Croatian: Osimertinib nije uzrokovao genetička oštećenja u in vitro i in vivo analizama.
English: There is limited experience with accidental overdoses in humans.
Croatian: Iskustvo sa slučajnim predoziranjem u ljudi je ograničeno.
English: • you are taking St. John's Wort (Hypericum perforatum).
Croatian: • ako uzimate gospinu travu (Hypericum perforatum).
English: Forty-two percent (42%) of patients had metastatic bone disease.
Croatian: Četrdeset i dva posto (42%) bolesnika imalo je metastatsku koštanu bolest.
English: It should be dropped in the water, without crushing, stirred until dispersed and immediately swallowed.
Croatian: Tabletu treba ubaciti u vodu bez drobljenja, miješati dok se ne rasprši i odmah progutati.
English: All patients received TAGRISSO at a dose of 80 mg once daily.
Croatian: Svi su bolesnici primali TAGRISSO u dozi od 80 mg jedanput dnevno.
English: There are no clinical data available to recommend a dose adjustment of TAGRISSO.
Croatian: Nema dostupnih kliničkih podataka koji bi uputili na preporuku za prilagodbu doze lijeka TAGRISSO.
English: In the evaluable for response population, 85% (223/262) had documentation of response at the time of the first scan (6 weeks); 94% (247/262) had documentation of response at the time of the second scan (12 weeks).
Croatian: U populaciji u kojoj se mogao ocijeniti odgovor, 85% (223/262) bolesnika imalo je zabilježen odgovor u trenutku prvog pregleda (6 tjedana); 94% (247/262) imalo je zabilježen odgovor u trenutku drugog pregleda (12 tjedana).
English: • Skin and nail problems - signs may include pain, itching, dry skin, rash, redness around the fingernails.
Croatian: • Problemi s kožom i noktima - znakovi mogu uključivati bol, svrbež, suhu kožu, osip i crvenilo oko noktiju.
English: The AUC and Cmax increased dose proportionally over 20 to 240 mg dose range.
Croatian: Vrijednosti AUC i Cmax povisile su se proporcionalno dozi u rasponu doza od 20 mg do 240 mg.
English: • asthe first medicine you receive for your cancer or
Croatian: • kao prvi lijek za liječenje raka ili
English: If you have trouble swallowing the tablet, you can mix it in water:
Croatian: Ako imate problema s gutanjem tablete, možete ju pomiješati s vodom: • Stavite tabletu u čašu.
English: Patients whose disease has not progressed after four cycles of platinum-based chemotherapy may receive pemetrexed maintenance therapy (pemetrexed 500 mg/m2 on Day 1 of every 21-day cycle).
Croatian: Bolesnici kojima bolest nije uznapredovala nakon četiri ciklusa kemoterapije na bazi platine mogli su primati terapiju održavanja pemetreksedom (pemetreksed u dozi od 500 mg/m2 1. dana svakog 21-dnevnog ciklusa).
English: Pathology findings in the testes seen following 1 month dosing were reversible in rats; however, a definitive statement on reversibility of these lesions in dogs cannot be made.
Croatian: Patološke promjene zamijećene u ispitivanih životinja nakon mjesec dana doziranja bile su reverzibilne u štakora; međutim, reverzibilnost ovih lezija u pasa ne može se definitivno odrediti.
English: Grade 3 and Grade 4 adverse reactions across both studies were 9.7% and 0.9%, respectively.
Croatian: Učestalost nuspojava stupnja 3 i stupnja 4 u oba ispitivanja bila je 9,7% odnosno 0,9%.
English: These effects were seen at a maternally tolerated dose of 20 mg/kg where exposure was equivalent to the human exposure at the recommended dose of 80 mg daily (based on total AUC).
Croatian: Ovi učinci zamijećeni su pri dozama podnošljivima za majku od 20 mg/kg, pri čemu je izloženost bila ekvivalentna izloženosti u ljudi pri preporučenoj dozi od 80 mg dnevno (na temelju ukupne AUC).
English: There is insufficient information on the excretion of osimertinib or its metabolites in animal milk.
Croatian: Nema dovoljno podataka o izlučivanju osimertiniba ili njegovih metabolita u mlijeko životinja.
English: Until additional data become available, use in patients with severe hepatic impairment is not recommended (see section 5.2).
Croatian: Dok ne postanu dostupni dodatni podaci, primjena u bolesnika s teškim oštećenjem funkcije jetre se ne preporučuje (vidjeti dio 5.2).
English: Based on in vitro data, osimertinib is an inhibitor of BCRP and P-gp (see section 4.5).
Croatian: Na temelju in vitro podataka, osimertinib je inhibitor BCRP-a i P-gp-a (vidjeti dio 4.5).
English: If you are taking any of the medicines listed above, tell your doctor before taking TAGRISSO.
Croatian: Ako uzimate neki od gore navedenih lijekova, obavijestite svog liječnika prije nego počnete uzimati TAGRISSO.
English: • in certain circumstances if you have beentreated for your cancer before with other protein kinase inhibitor medicines.
Croatian: • u određenim okolnostima ako ste prethodno primali druge inhibitore protein kinaze za liječenje raka
English: • Bosentan - used for high blood pressure in the lungs.
Croatian: • Bosentan - koristi se za liječenje visokog tlaka u plućima.
English: Dose reduction guidelines for adverse reactions toxicities are provided in Table 1.
Croatian: Smjernice za smanjenje doze u slučaju toksičnosti nuspojava navedene su u Tablici 1.
English: Driving and using machines TAGRISSO has no or no marked influence on the ability to drive and use machines.
Croatian: Upravljanje vozilima i strojevima TAGRISSO ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima ili strojevima.
English: Randomisation was stratified by EGFR mutation type (Ex19del or L858R) and ethnicity (Asian or non-Asian).
Croatian: Randomizacija je bila stratificirana prema tipu mutacije EGFR-a (delecija eksona 19 ili L858R) i etničkoj pripadnosti (Azijci i ostali).
English: Based on population PK analysis, there was no relationship between markers of hepatic function (ALT, AST, bilirubin) and osimertinib exposure.
Croatian: Na temelju populacijske farmakokinetičke analize, nije bilo odnosa između pokazatelja jetrene funkcije (ALT, AST, bilirubin) i izloženosti osimertinibu.
English: The OS analysis was not adjusted for the potentially confounding effects of crossover (94 [67%] patients on the chemotherapy arm received subsequent osimertinib treatment).
Croatian: Analiza OS-a nije bila prilagođena za potencijalno ometajuće učinke prelaska na drugo liječenje (94 [67%] bolesnika u skupini liječenoj kemoterapijom kasnije je primalo osimertinib).
English: Forty-seven percent (47%) of patients had metastatic bone disease.
Croatian: Četrdeset i sedam posto (47%) bolesnika imalo je metastatsku koštanu bolest.